1. Home
  2. OBAI vs KPRX Comparison

OBAI vs KPRX Comparison

Compare OBAI & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

OBAI

TG-17 Inc. Common Stock

N/A

Current Price

$0.45

Market Cap

12.3M

ML Signal

N/A

Logo Kiora Pharmaceuticals Inc.

KPRX

Kiora Pharmaceuticals Inc.

HOLD

Current Price

$2.82

Market Cap

10.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OBAI
KPRX
Founded
2017
1998
Country
United States
United States
Employees
N/A
13
Industry
Telecommunications Equipment
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.3M
10.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
OBAI
KPRX
Price
$0.45
$2.82
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
460.2K
64.6K
Earning Date
05-27-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.43
$1.76
52 Week High
$19.95
$4.18

Technical Indicators

Market Signals
Indicator
OBAI
KPRX
Relative Strength Index (RSI) 23.95 67.56
Support Level $0.44 $2.57
Resistance Level $1.66 $2.94
Average True Range (ATR) 0.05 0.16
MACD 0.05 0.02
Stochastic Oscillator 6.87 94.36

Price Performance

Historical Comparison
OBAI
KPRX

About OBAI TG-17 Inc. Common Stock

Our Bond Inc is a personal security service through its AI-powered Preventive Personal Security platform. It is trusted by corporations, cities, and universities, and has already supported many security service requests, emergencies and life-saving interventions. The cloud-based Bond Preventative Personal Security Platform provides users with remote protective services via phone app (using its Bond Preventative Personal Security Platform) and with 24/7 support from its Personal Security Agents, who are in Bond Command Centers and can respond rapidly. It offers distinct services through its phone app (the Bond App) and fully automated Bond Command Centers. Geographically, the company operates in Israel, France, and United States. It derives maximum revenue from United States.

About KPRX Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Share on Social Networks: